Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

337
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
337
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

209
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
209
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

245
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
245
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

370
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
370
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

235
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
235
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

259
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
259

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroacoustic single-cell spectroscopy for morphological differentiation of red blood cells: An in silico feasibility study.

JASA express letters·2026
Same author

Letter to the Editor "Constructive Critique on CKM Implementation: Focusing on Non-Pharmacological Burden and Staging Utility" regarding: "Implementation Barriers to Evidence-Based Cardiovascular-Kidney-Metabolic Syndrome Management" by Davis et al. Heart Lung Circ. 2025;34:1060-1068.

Heart, lung & circulation·2026
Same author

Changes in bubble-cloud dissolution throughout the application of histotripsy pulses.

Physical review applied·2026
Same author

Accuracy of Artificial Intelligence-Based Models Versus Conventional Scoring Systems (APACHE, SOFA, and SAPS) in Predicting Mortality Among ICU Patients: A Systematic Review and Meta-Analysis.

Cureus·2026
Same author

Spectral fluctuations and crossovers in multilayer network.

Physical review. E·2026
Same author

Exploring Overlooked Mediators Linking Myocardial Infarction to Hematologic Malignancies.

JACC. CardioOncology·2026

Related Experiment Video

Updated: Aug 1, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

9.7K

Probiotics in IBS: A Treatment Boon or a Pill Bulk: RCT-based Analysis.

Himanshu Shekhar1, Pradhan1

  • 1Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.

The Journal of the Association of Physicians of India
|April 28, 2023
PubMed
Summary

Probiotics offer significant symptom relief for Irritable Bowel Disease (IBD) patients, particularly those with diarrhea-predominant symptoms. However, symptom improvement may be temporary, with some patients experiencing recurrence after discontinuing probiotics.

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

879
Analysis of Interactions between Endobiotics and Human Gut Microbiota Using In Vitro Bath Fermentation Systems
06:58

Analysis of Interactions between Endobiotics and Human Gut Microbiota Using In Vitro Bath Fermentation Systems

Published on: August 23, 2019

7.1K

Related Experiment Videos

Last Updated: Aug 1, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

9.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

879
Analysis of Interactions between Endobiotics and Human Gut Microbiota Using In Vitro Bath Fermentation Systems
06:58

Analysis of Interactions between Endobiotics and Human Gut Microbiota Using In Vitro Bath Fermentation Systems

Published on: August 23, 2019

7.1K

Area of Science:

  • Gastroenterology
  • Microbiology
  • Clinical Research

Background:

  • Irritable Bowel Disease (IBD) is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits.
  • Probiotics, live microorganisms conferring health benefits, are explored for their potential to modulate gut microbiota in IBD.
  • The efficacy of probiotics in managing IBD symptoms remains a subject of ongoing research and debate.

Purpose of the Study:

  • To evaluate the effectiveness of a probiotic formulation in alleviating symptoms of Irritable Bowel Disease (IBD).
  • To compare the impact of probiotics versus placebo in a randomized controlled trial (RCT) setting.
  • To assess the duration of symptom relief and recurrence rates after probiotic discontinuation.

Main Methods:

  • A single-blind randomized controlled trial (RCT) involving 72 patients diagnosed with Irritable Bowel Disease (IBD).
  • Participants were categorized into diarrhea-predominant, constipation-predominant, and mixed manifestation groups.
  • A probiotic formulation (Lactobacillus, Bifidobacterium, Streptococcus species) was administered and compared against a placebo.

Main Results:

  • Significant symptom improvement was observed in 29 out of 36 patients receiving probiotics, with 18 experiencing substantial relief.
  • Diarrhea-predominant IBD patients showed the greatest degree of symptom improvement.
  • Approximately 40% of patients reported symptom recurrence within four weeks of discontinuing probiotics, a statistically significant difference compared to the placebo group.

Conclusions:

  • Probiotics demonstrate a significant therapeutic benefit in managing functional gastrointestinal disorders like Irritable Bowel Disease (IBD).
  • Probiotic therapy can be a valuable, cost-effective option for patients seeking improved quality of life.
  • Further research is warranted to optimize probiotic use and address symptom recurrence in IBD management.